Clinical trials: Cholangiocarcinoma Cancer
Hilar Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma
RALPPS in Patients With Hilar and Intrahepatic Cholangiocarcinoma
Unsatisfactory immediate outcomes of Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in surgery of cholangiocarcinoma suggested that patients with biliary cancer should not be treated by ALPPS.
- Trial name
- NCT03320980
- Testing
- RALPPS, portal vein embolization + major liver resection
- Volunteers
- 30 people
- Sponsor
- Moscow Clinical Scientific Center
Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult
HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
The goal of this clinical trial is to evaluate in patients with advanced intrahepatic cholangiocarcinoma harboring FGFR2 fusion/rearrangement.
- Trial name
- NCT04353375
- Testing
- HMPL-453
- Where
- China
- Volunteers
- 235 people
- Sponsor
- Hutchmed
Cholangiocarcinoma, Bile Duct Cancer
Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma
This is a multi-centre, open-label, single arm phase 2 study to assess the efficacy of TRIFLURIDINE/TIPIRACIL, in patients with advanced cholangiocarcinoma as measured by median progression-free survival (PFS).
- Trial name
- MOCHA (NCT04076761)
- Testing
- Trifluridine/Tipiracil
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Sunnybrook Health Sciences Centre
Biliary Tract Neoplasms, Recurrence
A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
The purpose of this study is to assess the difference of safety and efficacy about Capecitabine and S-1 for treatment of patients with low-risk of recurrence after BTC surgery.
- Conditions
- Biliary Tract Neoplasms, Recurrence, Cholangiocarcinoma, Gall Bladder Cancer
- Trial name
- NCT04856761
- Testing
- S-1, Capecitabine
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Fudan University
Extrahepatic Cholangiocarcinoma
VEGF Signaling Promotes Cell Growth and Metastasis in Extrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway (ECC)
The investigators study the VEGF signaling in ECC cell lines,patients and its mechanism in ECC growth, proliferation and apoptosis.
- Trial name
- VEGF ECC (NCT02103179)
- Testing
- surgical treatment
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Pancreatic Cancer, Cholangiocarcinoma
Bile Duct Drainage After ERCP Failure: EUS-BD vs PTBD
The vast majority of patients with distal biliary, pancreatic head or uncinate process cancer have jaundice caused by distal malignant obstruction (DMO) of the common bile duct.
- Conditions
- Pancreatic Cancer, Cholangiocarcinoma, Biliary Obstruction
- Trial name
- BESTDRAIN (NCT05519605)
- Where
- Netherlands
- Volunteers
- 61 people
- Sponsor
- Radboud University Medical Center
Intrahepatic Cholangiocarcinoma
HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma
Primary liver cancer is the sixth most common cancer worldwide, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, of which intrahepatic cholangiocarcinoma accounts for 10%-15%.
- Trial name
- NCT05400902
- Testing
- HAIC Combined with Tislelizumab and Apatinib
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Binkui Li
Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
This phase II trial studies how well selumetinib and Akt inhibitor MK-2206 work in treating patients with refractory or advanced gallbladder or bile duct cancer that cannot be removed by surgery.
- Conditions
- Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder, Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer
- Trial name
- NCT01859182
- Testing
- selumetinib, Akt inhibitor MK2206, laboratory biomarker analysis
- Sponsor
- National Cancer Institute (NCI)
Hilar Cholangiocarcinoma
Safety Study of Liver Transplantation for Hilar Cholangiocarcinoma
Hilar cholangiocarcinoma is a highly malignant tumor. Surgical resection or simple liver transplantation leads to poor prognosis accompanied by high recurrence rate and low survival rate.
- Trial name
- NCT02178280
- Testing
- liver transplantation combined with neoadjuvant therapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Intrahepatic Cholangiocarcinoma
First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC
The median survival of intrahepatic cholangiocarcinoma remains less than one year, highlighting the need for new treatments. Hepatic arterial infusion chemotherapy (HAIC), especially with fluoropyrimidine-based regimens, has…
- Trial name
- NCT06370663
- Testing
- Radiotherapy, HAIC (GEMOX), Chemotherapy
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Shandong Cancer Hospital and Institute
Adverse Drug Event, Colon Cancer
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
The purpose of this study is to examine the benefits of a clinical implementation of a DPYD-genotype test to patients starting treatment with fluoropyrimidines (Fluorouracil (5-FU), capecitabine, tegafur).
- Conditions
- Adverse Drug Event, Colon Cancer, Breast Cancer, Pancreas Cancer
- Trial name
- NCT05266300
- Testing
- DPYD genotype
- Where
- Denmark
- Volunteers
- 722 people
- Sponsor
- University of Southern Denmark
Bile Duct Cancer, Biliary Cancer
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
Background: Bile duct cancer is cancer of the slender tubes of the biliary tract. These tubes carry bile through the liver. Such cancer tumors often have an abnormal or mutated gene.
- Conditions
- Bile Duct Cancer, Biliary Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma
- Trial name
- NCT04566133
- Testing
- Trametinib, Hydroxychloroquine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Biliary Tract Neoplasms, Cholangiocarcinoma
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Background: Biliary tract cancers are rare but they are serious. Researchers want to see if a certain drug helps the immune system fight cancer cells. The drug is called pembrolizumab.
- Conditions
- Biliary Tract Neoplasms, Cholangiocarcinoma, Bile Duct Cancer, Liver Cancer
- Trial name
- NCT03111732
- Testing
- Pembrolizumab (MK-3475), Oxaliplatin, Capecitabine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Cholangiocarcinoma
Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA
This study is a prospective, observational study designed to analyze the safety, tolerability, and efficacy of first-line treatment using the combination of gemcitabine and cisplatin plus anti-PD-1/PD-L1 antibodies for patients…
- Trial name
- NCT07291063
- Testing
- Anti-PD-1/PD-L1 antibody, Gemcitabine and Cisplatin Chemotherapy
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital
Intrahepatic Cholangiocarcinoma by AJCC V8 Stage
Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma
This study is designed to observe and evaluate the safety and the efficacy of the anti-programmed-death-1 antibody (anti-PD-1) Triprilumab in combination with chemotherapy of Gemcitabine PLUS Cisplatin in patients who were…
- Trial name
- NCT04413734
- Testing
- Combination therapy, Mono-chemotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang University
Cholangiocarcinoma, Pancreatic Cancer
T-EUS for Gastrointestinal Disorders: A Multicenter Registry
The purpose of this registry is to record information and evaluate the impact of Endoscopic Ultrasound (EUS) Guided Endoscopic retrograde cholangiopancreatography (ERCP) on the management of pancreatico-biliary disorders.
- Conditions
- Cholangiocarcinoma, Pancreatic Cancer, Bile Duct Cancer, Biliary Stricture
- Trial name
- EUSERCPReg (NCT01522573)
- Testing
- EUS guided ERCP
- Where
- 2 sites in United States, Brazil
- Volunteers
- 1,000 people
- Sponsor
- Weill Medical College of Cornell University
Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally…
- Conditions
- Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma
- Trial name
- SURF201 (NCT06160752)
- Testing
- Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles, Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Tyra Biosciences, Inc
Hepatocellular Carcinoma, HCC
Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L
Phase III, randomized, placebo-controlled, double-blinded trial aimed to seek the therapeutic benefit of hepcortespenlisimut-L (Hepko-V5) in subjects with advanced hepatocellular carcinoma.
- Conditions
- Hepatocellular Carcinoma, HCC, Liver Cancer
- Trial name
- Hepko-V5 (NCT02232490)
- Testing
- hepcortespenlisimut-L
- Where
- 2 sites in Mongolia
- Volunteers
- 120 people
- Sponsor
- Immunitor LLC
Unresectable Cholangiocarcinoma, Advanced/Metastatic Cholangiocarcinoma
A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy
The purpose of this study is to confirm the efficacy and safety of pemigatinib in participants with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 fusion or rearrangements after at least 1 prior line…
- Trial name
- FIGHT-214 (NCT07862998)
- Testing
- Pemigatinib
- Volunteers
- 72 people
- Sponsor
- Incyte Corporation
Intrahepatic Cholangiocarcinoma
Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma
The purpose of this research is to evaluate whether adding histotripsy to maintenance durvalumab increases immune response and to assess the safety of this combination for participants with advanced intrahepatic…
- Trial name
- CODAH (NCT07766187)
- Testing
- Histotripsy, Durvalumab, Biopsy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Wisconsin, Madison
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.